Yunkang Group Limited (HKG:2325)
Hong Kong · Delayed Price · Currency is HKD 0.7600
-0.0200 (-2.63%)
Apr 20, 2026, 3:55 PM HKT
Yunkang Group Revenue
In the year 2025, Yunkang Group had annual revenue of 601.39M CNY, down -15.52%. Yunkang Group had revenue of 288.17M in the half year ending December 31, 2025, a decrease of -30.50%.
Revenue
601.39M CNY
Revenue Growth
-15.52%
P/S Ratio
0.66
Revenue / Employee
524.77K CNY
Employees
1,146
Market Cap
444.86M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 601.39M | -110.50M | -15.52% |
| Dec 31, 2024 | 711.88M | -179.62M | -20.15% |
| Dec 31, 2023 | 891.50M | -2.86B | -76.27% |
| Dec 31, 2022 | 3.76B | 2.06B | 121.38% |
| Dec 31, 2021 | 1.70B | 496.42M | 41.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi XDC Cayman | 6.61B |
| Adicon Holdings | 2.94B |
| Kindstar Globalgene Technology | 1.04B |
| Mega Genomics | 275.03M |
| Biosino Bio-Technology and Science Incorporation | 205.08M |
| Guanze Medical Information Industry (Holding) | 98.42M |
| King International Investment | 77.50M |
| China Biotech Services Holdings | 73.50M |